Sermorelin Patent Status and Generic Timeline

How Sermorelin Works: Mechanism of Action

Sermorelin acetate is the synthetic 29-amino-acid fragment corresponding to the first 29 residues of human growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor on anterior pituitary somatotroph cells, triggering cyclic AMP-mediated signal transduction that stimulates endogenous growth hormone (GH) synthesis and pulsatile release [1]. Unlike exogenous recombinant GH (somatropin), sermorelin preserves the hypothalamic-pituitary feedback loop. GH secretion remains subject to somatostatin inhibition, which prevents supraphysiologic GH peaks.

Walker et al. demonstrated in a multicenter pediatric trial (N=71) that sermorelin acetate 1 mcg/kg SC daily increased growth velocity from a baseline of 4.2 cm/year to 7.0 cm/year over 12 months in children with idiopathic GH deficiency [1]. The peptide's short plasma half-life (10 to 20 minutes) means it acts as a secretagogue pulse rather than a sustained GH elevation. This pharmacokinetic profile is one reason clinicians favor bedtime dosing: it amplifies the natural nocturnal GH surge without suppressing daytime somatostatin tone [2].

Because the 29-amino-acid sequence retains full biological activity at the GHRH receptor, no additional residues are required for receptor binding. This was confirmed by structure-activity studies at the Salk Institute in the 1980s, which showed residues 1-29 are both necessary and sufficient for receptor activation [3].

Original Patent History and Expiration

The composition-of-matter patent for sermorelin acetate traces to early GHRH isolation work. After Guillemin and colleagues characterized GHRH from a pancreatic tumor in 1982, Serono Laboratories (now EMD Serono) developed the truncated 1-29 analog for clinical use [3]. U.S. Patent 4,518,586, covering synthetic GHRH analogs including the 1-29 fragment, was filed in 1983 and issued in 1985 with a 17-year term under pre-1995 patent law.

That patent expired in 2002. A related process patent (U.S. 4,622,312) covering solid-phase peptide synthesis methods for GHRH fragments expired in 2003. By the mid-2000s, no valid composition or method-of-use patents blocked generic manufacture of the 29-amino-acid sequence.

The absence of patent protection after 2003 did not produce a wave of generic filings. The reason is economic, not legal. Sermorelin's market size was small. The branded product served a narrow diagnostic indication (single-dose IV administration to assess pituitary GH reserve), and the therapeutic subcutaneous formulation (Geref, approved 1997 for pediatric GHD) never gained broad commercial traction against recombinant GH products like Humatrope and Genotropin [4].

FDA Approval, Withdrawal, and Current Regulatory Status

The FDA approved sermorelin acetate for injection (Geref) in 1997 under NDA 020604 for the diagnostic assessment of pituitary capacity to secrete growth hormone [4]. A separate pediatric therapeutic indication existed briefly but was not commercially sustained.

In 2008, EMD Serono voluntarily withdrew Geref from the U.S. market. The FDA's withdrawal notice explicitly states the removal was "not for reasons of safety or effectiveness" [5]. The company cited insufficient commercial viability. The Orange Book no longer lists any sermorelin-containing product.

This withdrawal created an unusual regulatory situation. With no Reference Listed Drug (RLD) on the market, a standard ANDA (Abbreviated New Drug Application) pathway for a generic is not straightforward. A potential manufacturer would need to file either a 505(b)(2) NDA referencing published literature or petition for suitability. Given sermorelin's relatively small market and the availability of the peptide through compounding, no pharmaceutical company has pursued either route as of May 2026.

The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations confirms zero active ANDAs or 505(b)(2) applications for sermorelin acetate [5].

The 503A Compounding Pathway

Since 2008, sermorelin has been available in the United States exclusively through Section 503A compounding pharmacies operating under the Federal Food, Drug, and Cosmetic Act. Under 503A, a licensed pharmacist may compound sermorelin acetate for an individual patient based on a valid prescription from a licensed prescriber [6].

Key regulatory constraints for 503A sermorelin:

• The prescriber must establish a valid patient-prescriber relationship
• The pharmacy must compound in response to individual prescriptions (not batch manufacturing for office stock without patient-specific orders, unless state law permits anticipatory compounding)
• The compounded product cannot be "essentially a copy" of a commercially available drug. Because no FDA-approved sermorelin exists, this restriction does not apply
• The bulk sermorelin acetate used must meet USP compendial standards or be sourced from an FDA-registered facility

The FDA's Bulk Drug Substances That Can Be Used in Compounding Under Section 503A confirms sermorelin acetate's eligibility [6]. It appears on Category 1 of the FDA's bulk drug substance evaluation list, meaning it has been found acceptable for 503A compounding.

Why No Traditional Generic Exists (and Likely Won't)

Three factors explain the absence of a conventional generic sermorelin product.

No Reference Listed Drug. The ANDA pathway requires bioequivalence to an existing RLD. With Geref withdrawn, no RLD exists. A 505(b)(2) application is possible but requires new clinical data, which raises development costs beyond what the market supports.

Small addressable market. Recombinant GH (somatropin) dominates the pediatric GHD market with over $3 billion in annual U.S. sales across multiple branded and biosimilar products [7]. Sermorelin's clinical niche is narrower: adults seeking GH optimization through a secretagogue rather than direct GH replacement. This population, while growing in anti-aging and wellness medicine, does not generate the revenue projections that justify a full NDA program.

Compounding satisfies demand. At $100, $300 per month from compounding pharmacies, sermorelin is already accessible without insurance coverage. A generic manufacturer would need to price competitively against compounders while absorbing NDA development costs of $5, $15 million for a peptide product. The economics do not close.

The Endocrine Society's 2006 Clinical Practice Guideline on GH use in adults does not recommend GHRH analogs as first-line therapy, noting insufficient long-term efficacy data compared to recombinant GH [8]. This guideline position further reduces commercial incentive for a generic filing.

Comparison to Other GH Secretagogues and Patent Considerations

Sermorelin occupies one position in a broader class of GH secretagogues with varying patent statuses.

Tesamorelin (Egrifta, Theratechnologies): FDA-approved 2010 for HIV-associated lipodystrophy. Protected by patents extending to approximately 2027. A 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification. Not interchangeable with sermorelin [9].

Ipamorelin: A synthetic pentapeptide ghrelin-receptor agonist. Never FDA-approved. Available through 503A compounding. Original research patents expired.

CJC-1295 (with or without DAC): A modified GHRH analog with extended half-life. Never FDA-approved. Available through 503A compounding. Research patents held by ConjuChem (now dissolved) have expired.

MK-677 (ibutamoren): An oral ghrelin mimetic. Never FDA-approved despite Phase II trials. Composition patents held by Merck have expired [10].

Among these, only tesamorelin carries active patent protection and FDA approval. The rest, like sermorelin, exist in the compounding space with expired or no relevant patents.

Clinical Evidence Base and Its Effect on Regulatory Interest

The evidence supporting sermorelin's therapeutic use in adults remains limited to small, short-duration studies. This thin evidence base is both a consequence and a cause of the lack of commercial development.

Walker et al. (1990) remains the most-cited controlled trial, demonstrating efficacy in pediatric GHD with growth velocity increases of 67% over baseline [1]. Adult data comes primarily from open-label studies. Vittone et al. (1997) showed that sermorelin 2 mg SC daily for 14 days increased 24-hour integrated GH concentration by 68% in healthy older men (N=8), but did not assess body composition or functional outcomes [2].

A systematic review framework for GHRH analogs published in the Journal of Clinical Endocrinology & Metabolism noted that "no randomized controlled trial of sufficient duration has evaluated the effect of GHRH analogs on clinically meaningful endpoints (fracture, lean mass, quality of life) in GH-deficient adults" [8]. Without such data, the FDA would require a new clinical program for any NDA or 505(b)(2) submission, making the regulatory pathway expensive relative to market opportunity.

The American Association of Clinical Endocrinologists (AACE) 2019 consensus statement on GH use acknowledges GHRH analogs as physiologically rational but does not endorse their use outside research settings due to insufficient Phase III data [11].

Future Outlook: 2026 and Beyond

Several scenarios could change sermorelin's availability status.

FDA compounding guidance changes. If the FDA reclassifies or restricts sermorelin's 503A eligibility (as it has done with other peptides), access could narrow significantly. The FDA's 2023 proposed rule on bulk drug substances for outsourcing facilities (503B) specifically included sermorelin on its "under evaluation" list, though no final action restricting it has occurred as of May 2026 [6].

Telehealth-driven demand growth. The expansion of hormone optimization telehealth platforms has increased sermorelin prescribing volume substantially since 2020. If demand reaches a threshold where a branded product becomes commercially viable, a 505(b)(2) sponsor could emerge. No such program has been publicly announced.

Biosimilar/peptide-specific pathways. The FDA has not established a dedicated abbreviated pathway for synthetic peptides under 40 amino acids. Sermorelin (29 amino acids) falls below the threshold for biological product classification (which applies to larger proteins), keeping it in the drug/NDA framework. Legislative proposals for a "follow-on peptide" pathway have been discussed in industry white papers but have not advanced to bill status.

The most probable scenario through 2028 remains the status quo: sermorelin continues as a compounded-only peptide with no patent barriers, no FDA-approved product, and no generic filing on the horizon.

Prescribing Considerations in the Current Access Environment

Clinicians prescribing sermorelin through 503A pharmacies should verify three elements. First, confirm the compounding pharmacy holds current state licensure and operates under 503A (individual prescriptions) rather than 503B (outsourcing facility) rules, as compliance standards differ. Second, request a Certificate of Analysis (CoA) confirming peptide purity above 98% and endotoxin levels below 20 EU/mL. Third, counsel patients that compounded sermorelin is not FDA-approved, is not covered by insurance, and that evidence supporting its use in adult GH optimization is preliminary.

Standard adult dosing in clinical practice is 200 to 300 mcg subcutaneously at bedtime, titrated based on IGF-1 response measured at 4 to 6 week intervals. Target IGF-1 is typically the upper quartile of the age-adjusted reference range [8]. Sermorelin should be reconstituted with bacteriostatic water and stored at 2, 8°C, with a beyond-use date typically set at 28 days per USP 797 standards.